Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and PD of IBI3035 and Awiqli in Healthy Male Subjects
NCT07591519Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- May 2026
- Primary completion
- Jul 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IBI3035 in diabetes mellitus (DM) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Area Under the Blood Drug Concentration-Time Curve from 0 to 168 hours and Area Under Curve Glucose Infusion Rate 0-168h. Started May 2026; status: recruiting.
02
Drugs
IBI3035
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07591519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591519.